Internet Archive Scholar

Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities [post]

Farrukh Vohidov, Jannik N. Andersen, Kyriakos D. Economides, Michail V. Shipitsin, Olga Burenkova, James C. Ackley, Bhavatarini Vangamudi, Nolan M. Gallagher, Peyton Shieh, Matthew R. Golder, Jenny Liu, William K. Dahlberg (+18 others)
2020 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.3 MB)
https://web.archive.org/web/20210428043642/https://s3-eu-west-1.amazonaws.com/pstorage-chemrxiv-899408398289/25502927/ChemRxiv_Manuscript.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

<div><p>Prodrugs engineered for preferential activation in diseased versus normal tissues offer immense potential to improve the therapeutic index of preclinical and clinical-stage active pharmaceutical ingredients that either cannot be developed otherwise or whose efficacy or tolerability it is highly desirable to improve. Such approaches, however, often suffer from trial-and-error design, precluding predictive design and optimization. Here, using BET bromodomain inhibitors (BETi)—a class of
more » ... igenetic regulators with proven anti-cancer activity but clinical development hindered by systemic adverse effects–– we introduce a platform that overcomes these challenges. Through tuning of traceless linkers appended to a "brush prodrug" scaffold, we demonstrate that it is possible to correlate <i>in vitro </i>prodrug activation kinetics with <i>in vivo </i>tumor pharmacokinetics, leading to novel BETi prodrugs with enhanced anti-tumor efficacy and devoid of dose-limiting toxicities. This work has immediate clinical implications, introducing principles for the predictive design of prodrugs and potentially overcoming hurdles in drug development. </p></div>
doi:10.26434/chemrxiv.13241966.v1 fatcat:h2my3vqxgzbzpkcixie7p6shri
Open Access
Citation

Farrukh Vohidov, Jannik N. Andersen, Kyriakos D. Economides, Michail V. Shipitsin, Olga Burenkova, James C. Ackley, Bhavatarini Vangamudi, Nolan M. Gallagher, Peyton Shieh, Matthew R. Golder, Jenny Liu, William K. Dahlberg, Hung V.-T. Nguyen, Deborah J. C. Ehrlich, Julie Kim, Sung Jin Huh, Allison M. Neenan, Joelle Baddour, Sattanathan Paramasivan, Elisa de Stanchina, Gaurab KC, David J. Turnquist, Jennifer K. Saucier-Sawyer, Paul W. Kopesky, Samantha W. Brady, Michael J. Jessel, Lawrence A. Reiter, Donald E. Chickering, Jeremiah Johnson, Peter Blume-Jensen. "Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities." (2020)